A Randomized, Double-blind, Placebo-controlled Phase 2a Study of ARO-RAGE Inhalation Solution to Assess Efficacy on Small Airway Dysfunction in Allergen-Induced Mild Asthma (ARORAGE-2001)

Summary

This study is for patients with allergic asthma. Asthma can cause the airways of the lungs to narrow (airways are the tubes which carry air into the lungs). This can cause wheezing, shortness of breath, chest tightness and/or cough. This airway narrowing is often due to chronic inflammation in the lungs.
The investigational study drug (known as ARO-RAGE) is being developed to treat asthmatics by reducing the amount of a protein in the lung (called Receptor for Advanced Glycation End-products, or RAGE). The RAGE protein may cause inflammation in the lung airways, so it is possible that ARO-RAGE will decrease this inflammation. This may result in better airflow, improved symptoms, and fewer asthma flare-ups (exacerbations). It is also possible that you may receive no benefit and it may not result in these improved symptoms.

Eligibility

Currently recruiting participants: Yes

Eligible ages: 18 to 65

Accepts healthy participants: Yes

Inclusion criteria:

1. You are 18-65 years old
2. You have allergic asthma (your asthma flares up only with exposure to allergic triggers, such as animals or pollen).

Exclusion criteria:

1. You are pregnant, or plan to become pregnant.
2. You have significant health issues other than asthma.

Participate

Fill out the following form if you want to participate in this research

Method of contact

UCalgary Notice of Collection
The University of Calgary (UCalgary) respects your privacy and is committed to ensuring the privacy of all students, staff, and community members. Your personal information is being collected under the authority of section 4(c) of the Protection of Privacy Act (POPA). It will be collected, used and disclosed for the purposes outlined in UCalgary’s Notice of Collection, Use and Disclosure of Personal Information and managed in accordance with UCalgary’s Privacy Management Program. Your personal information may be input into automated systems to generate content or make decisions, recommendations, or predictions. If you have questions regarding this notice or UCalgary’s collection, use, or disclosure of your personal information, please contact accessandprivacy@ucalgary.ca.

Additional information

Contact information

Study coordinator, Curtis Dumonceaux

Principal investigator:

Richard Leigh

Clinical trial:

Yes

REB-ID:

REB25-1806